Clinical Trials Logo
  1. Home
  2. Cancer
  3. NCT02866149
  4. Details
NCT02866149 Clinical Trial

Analysis of Circulating Tumor Markers in the Blood (ALCINA)

Cancer Clinical Trial

— ALCINA  

Official title:
Analysis of Circulating Tumor Markers in the Blood

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT02866149
Other study ID # IC 2015-02
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 2015
Est. completion date September 2025

Study information
Verified date September 2023
Source Institut Curie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.

Description:

Exploratory multi-cohort study including different types of cancer (different organs and/or different histological types). Each kind of blood-borne biological markers analyses corresponds to a cohort.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 682
Est. completion date September 2025
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient with any tumoral disease (proven or suspected), of any type and stage 2. More than18 years old 3. Signed informed consent form Additional inclusion criteria if a tumor sample is needed: 4. Tumor considered as accessible by biopsy 5. Normal blood coagulation tests on the last blood analysis Non-inclusion Criteria: 1. Patient in detention or protected by the law 2. Patient who cannot comply with the study follow up for geographical, social or psychological reasons Additional non-inclusion criteria if a tumor sample is needed: 3. Anticoagulant or antiaggregant that cannot be interrupted for the biopsy 4. central-nervous system metastases only (unless a diagnostic or curative surgery is planned before the inclusion in the study)

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Blood sampling
Up to 5 blood samplings can be performed at different time points
Procedure:
• Tumor sampling
One tumor sampling can be performed, if applicable
Other:
• Stool sampling
Up to 5 blood samplings can be performed at different time points

Locations
Country Name City State
France Centre Georges François Leclerc Dijon
France Institut du Cancer de Montpellier Montpellier
France Institut Curie (Paris hospital) Paris
France Institut Mutualiste Montsouris Paris
France Institut Curie (St Cloud hospital) Saint-cloud

Sponsors (1)
Lead Sponsor Collaborator
Institut Curie

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Feasibility of the analysis of different blood-borne tumor biomarkers Success rate of the tested detection techniques. The success rate of a given detection technique is calculated by the ratio " detection success " / " number of screened patients ". 18 months
Secondary Correlation with biological and clinical data Number of biological analysis results correlated to clinical data. Establishment of a proof of concept 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients